Biogen, Isis unite for the 4th time to develop neurological drugs

09/10/2013 | Reuters · Genetic Engineering & Biotechnology News

Biogen Idec signed a deal with Isis Pharmaceuticals to develop new treatments for neurological diseases using the latter's antisense technology. The current deal, which entitles Isis to $100 million upfront, is the fourth collaboration between the firms in the past two years. Isis will get milestone and licensing fees plus sales royalties on products arising from the collaboration.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ